JP2010523522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523522A5 JP2010523522A5 JP2010501495A JP2010501495A JP2010523522A5 JP 2010523522 A5 JP2010523522 A5 JP 2010523522A5 JP 2010501495 A JP2010501495 A JP 2010501495A JP 2010501495 A JP2010501495 A JP 2010501495A JP 2010523522 A5 JP2010523522 A5 JP 2010523522A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cor
- formula
- optionally substituted
- conr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims 1
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical group N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07380088 | 2007-04-02 | ||
| PCT/EP2008/053842 WO2008119792A1 (en) | 2007-04-02 | 2008-03-31 | Pyrrolopyrimidine derivatives as jak3 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010523522A JP2010523522A (ja) | 2010-07-15 |
| JP2010523522A5 true JP2010523522A5 (enExample) | 2011-05-19 |
Family
ID=38475914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501495A Withdrawn JP2010523522A (ja) | 2007-04-02 | 2008-03-31 | Ｊａｋ３阻害剤としてのピロロピリミジン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110160185A9 (enExample) |
| EP (1) | EP2142550A1 (enExample) |
| JP (1) | JP2010523522A (enExample) |
| KR (1) | KR20100015353A (enExample) |
| CN (1) | CN101679440A (enExample) |
| AR (1) | AR065901A1 (enExample) |
| AU (1) | AU2008234822A1 (enExample) |
| BR (1) | BRPI0809992A2 (enExample) |
| CA (1) | CA2682646A1 (enExample) |
| CL (1) | CL2008000946A1 (enExample) |
| IL (1) | IL201073A0 (enExample) |
| MX (1) | MX2009010595A (enExample) |
| PE (1) | PE20090996A1 (enExample) |
| RU (1) | RU2009140319A (enExample) |
| TW (1) | TW200904442A (enExample) |
| WO (1) | WO2008119792A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026107A1 (en) | 2007-08-17 | 2009-02-26 | Portola Pharmaceuticals, Inc. | Protein kinase inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
| WO2009131687A2 (en) * | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| TW201024298A (en) * | 2008-09-23 | 2010-07-01 | Palau Pharma Sa | (R)-3-(N,N-dimethylamino)pyrrolidine derivatives |
| CN102232076B (zh) * | 2008-12-05 | 2014-12-31 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪基脲激酶抑制剂 |
| HRP20150701T1 (hr) * | 2009-06-08 | 2015-08-28 | Takeda Pharmaceutical Company Limited | Spojevi dihidropirolonaftiridinona kao inhibitori jak |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| AU2010311378B2 (en) * | 2009-10-29 | 2014-04-24 | Vectura Limited | N-containing heteroaryl derivatives as JAK3 kinase inhibitors |
| JP2013533868A (ja) * | 2010-07-09 | 2013-08-29 | レオ ファーマ アクティーゼルスカブ | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 |
| JP5749341B2 (ja) | 2010-08-20 | 2015-07-15 | ハチソン メディファーマ リミテッド | ピロロピリミジン化合物およびその使用 |
| WO2012030924A1 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Azolopyridine and azolopyrimidine compounds and methods of use thereof |
| WO2012030912A1 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | 7-cyclylquinazoline derivatives and methods of use thereof |
| JP6039683B2 (ja) | 2011-11-23 | 2016-12-07 | ポートラ ファーマシューティカルズ， インコーポレイテッド | ピラジンキナーゼ阻害剤 |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| EP2947084B8 (en) | 2013-01-18 | 2021-03-10 | Guangzhou Maxinovel Pharmaceuticals Co. | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof |
| KR101657616B1 (ko) * | 2013-05-24 | 2016-09-19 | 주식회사유한양행 | 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법 |
| CN106458914B (zh) * | 2014-03-28 | 2020-01-14 | 常州捷凯医药科技有限公司 | 作为axl抑制剂的杂环化合物 |
| CN105315285B (zh) * | 2014-07-25 | 2017-12-08 | 上海海雁医药科技有限公司 | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 |
| NO2721710T3 (enExample) * | 2014-08-21 | 2018-03-31 | ||
| CN105732636B (zh) * | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| EP3778605A3 (en) | 2015-02-13 | 2021-03-10 | Dana Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
| CN104876934B (zh) * | 2015-05-12 | 2017-08-11 | 山东大学 | 一种含氮杂环苯基哌啶类化合物及其制备方法与应用 |
| KR20180011272A (ko) * | 2015-05-28 | 2018-01-31 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 키나제 저해제로서 나프티리딘 화합물 |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG10201913989QA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| CN110526915B (zh) * | 2018-05-25 | 2022-02-01 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂的制备方法 |
| MX2021005334A (es) * | 2018-11-05 | 2021-06-23 | Avista Pharma Solutions Inc | Compuestos quimicos. |
| EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| WO2020212395A1 (en) | 2019-04-16 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| KR20200133188A (ko) * | 2019-05-17 | 2020-11-26 | 보로노이바이오 주식회사 | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 |
| CN110183471B (zh) * | 2019-05-21 | 2022-02-15 | 江苏大学 | 一种哌嗪类衍生物及制备方法及应用 |
| CN110317176A (zh) * | 2019-07-04 | 2019-10-11 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
| US20240166635A1 (en) * | 2020-11-27 | 2024-05-23 | Anrui Biomedical Technology (Guangzhou) Co.,Ltd. | Aminoheteroaryl kinase inhibitors |
| WO2022117012A1 (zh) * | 2020-12-02 | 2022-06-09 | 百极弘烨（广东）医药科技有限公司 | 螺环jak抑制剂、含其的药物组合物及其应用 |
| KR102666918B1 (ko) * | 2021-04-08 | 2024-05-20 | 주식회사 스탠다임 | 신규한 lrrk2 억제제 |
| US20250283174A1 (en) | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
| JP2025522733A (ja) * | 2022-06-29 | 2025-07-17 | アルコン インコーポレイテッド | アゼチジニルピリミジンおよびｊａｋ阻害剤としてのその使用 |
| CN118005609B (zh) * | 2022-11-09 | 2025-06-17 | 沈阳药科大学 | 2-氨基嘧啶类化合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20004727A3 (cs) * | 1998-06-19 | 2002-03-13 | Pfizer Products Inc. | Deriváty pyrrolo[2,3-d] pyrimidinu |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| ES2320487T3 (es) * | 2005-02-03 | 2009-05-22 | Vertex Pharmaceuticals, Inc. | Pirrolopirimidinas utiles como inhibidores de proteina quinasas. |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
-
2008
- 2008-03-31 AU AU2008234822A patent/AU2008234822A1/en not_active Abandoned
- 2008-03-31 MX MX2009010595A patent/MX2009010595A/es not_active Application Discontinuation
- 2008-03-31 CA CA002682646A patent/CA2682646A1/en not_active Abandoned
- 2008-03-31 CN CN200880015843A patent/CN101679440A/zh active Pending
- 2008-03-31 JP JP2010501495A patent/JP2010523522A/ja not_active Withdrawn
- 2008-03-31 US US12/594,228 patent/US20110160185A9/en not_active Abandoned
- 2008-03-31 BR BRPI0809992-8A2A patent/BRPI0809992A2/pt not_active IP Right Cessation
- 2008-03-31 WO PCT/EP2008/053842 patent/WO2008119792A1/en not_active Ceased
- 2008-03-31 PE PE2008000586A patent/PE20090996A1/es not_active Application Discontinuation
- 2008-03-31 KR KR1020097020666A patent/KR20100015353A/ko not_active Withdrawn
- 2008-03-31 RU RU2009140319/04A patent/RU2009140319A/ru not_active Application Discontinuation
- 2008-03-31 EP EP08735625A patent/EP2142550A1/en not_active Withdrawn
- 2008-03-31 AR ARP080101351A patent/AR065901A1/es not_active Application Discontinuation
- 2008-04-01 TW TW097111869A patent/TW200904442A/zh unknown
- 2008-04-01 CL CL200800946A patent/CL2008000946A1/es unknown
-
2009
- 2009-09-21 IL IL201073A patent/IL201073A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010523522A5 (enExample) | ||
| JP2013510120A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| JP2014507455A5 (enExample) | ||
| JP2013545785A5 (enExample) | ||
| JP2004531563A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2010504344A5 (enExample) | ||
| JP2016523270A5 (enExample) | ||
| JP2013523614A5 (enExample) | ||
| JP2013509431A5 (enExample) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| JP2013532652A5 (enExample) | ||
| JP2015506348A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| TW200840567A (en) | Novel oxadiazole compounds | |
| JP2014510774A5 (enExample) | ||
| KR20140145615A (ko) | 항바이러스 치료를 위한 화합물 및 방법 | |
| JP2012533546A5 (enExample) | ||
| JP2015508092A5 (enExample) | ||
| JP2016505010A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2017525699A5 (enExample) | ||
| JP2014518543A5 (enExample) |